Toronto, ON (PRWEB)
October 04, 2016
ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced it has issued a new scientific white paper entitled: ‘Critical Insight – Toxic soluble Amyloid beta oligomers (“prions”), not plaque, drive pathogenesis in Alzheimer’s disease’. This is one of a series of commentaries from the ProMIS scientific team offering insight on the Company’s emerging product portfolio and Alzheimer’s disease (AD) science in the popular press.
“The recent Nature publication discussing the results of Biogen’s PRIME study, completed in 2015, focused on the role of aducanumab in reducing plaque burden in AD. However, there…